Open AccessThrombosis Risk Assessment In The COVID-19 Era
Author(s) -
Joseph A. Caprini
Publication year - 2020
Publication title -
revista ciências em saúde
Language(s) - English
Resource type - Journals
ISSN - 2236-3785
DOI - 10.21876/rcshci.v10i3.1006
Subject(s) - medicine , thrombosis , anticoagulant , intensive care medicine , risk assessment , covid-19 , pandemic , anticoagulant therapy , venous thromboembolism , pulmonary embolism , venous thrombosis , disease , infectious disease (medical specialty) , computer security , computer science
The appearance of the coronavirus pandemic has prompted a renewed interest in thrombosis risk assessment, particularly since this disease is associated with a high risk of thrombotic events. It is known that the number one preventable cause of death in hospitalized patients including those having surgical procedures is fatal pulmonary emboli. There is also high-quality data that the use of anticoagulant drugs in the proper dose, and for the period of time shown to be efficacious, will prevent most fatal events. It is true that even with the use of the best anticoagulant regimes venous thromboembolic events (VTE) can still occur but are rarely fatal. We also realize that providing adequate anticoagulant prophylaxis for the entire period of risk is the key to preventing these deaths. Thrombosis risk scoring identifies who's at risk for these emboli and guides physician choices for appropriate preventive measures.